Drug intelligence / Profile preview

SAR444500

Development stage: Preclinical
Lead developer: Sanofi

Overview

SAR444500 is an investigational therapeutic candidate originally developed by Sanofi and out-licensed to Babylon Biosciences in July 2026. Babylon Biosciences is a biotechnology company focused on discovering and developing therapeutics for neurodegenerative diseases, particularly Alzheimer's disease, by rescuing essential brain functions rather than clearing emergent pathology. While specific details regarding the target, modality, and clinical phase of SAR444500 remain undisclosed, its development is aligned with Babylon's focus on brain diseases.

Beyond the preview

Go deeper on SAR444500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR444500.

Explore the full profile